ESC Premium Access

Determinants of antithrombotic treatment of patients with AF: baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with AF (IMPACT-AF)

Presentation

About the speaker

Professor Dragos Vinereanu

University of Medicine and Pharmacy Carol Davila, Bucharest (Romania)
12 presentations
1 follower

53 more presentations in this session

Differences between randomized controlled clinical trials and real-world atrial fibrillation patients treated with oral anticoagulants - do we treat the same patients? Results from the CRAFT study

Speaker: Doctor A. Tyminska (Warsaw, PL)

Thumbnail

Which factors influence the choice of a non-vitamin K oral anticoagulant over warfarin for stroke prevention among atrial fibrillation patients? Insights from the prospective SPRINT-AF registry.

Speaker: Doctor M. Gupta (Toronto, CA)

Thumbnail

Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in germany - insights from the reload study

Speaker: Professor H. Bonnemeier (Kiel, DE)

Thumbnail

Increased thromboprophylactic treatment of patients with atrial fibrillation after the introduction of NOACs - an analysis of sex and gender differences

Speaker: Ms D. Loikas (Stockholm, SE)

Thumbnail

Comparison of stroke- and bleed-related healthcare resource utilization (HCRU) among patients with non-valvular atrial fibrillation (NVAF), newly treated with oral anti-coagulants (OACs)

Speaker: Doctor J. Franchino-Elder (Ridgefield, US)

Thumbnail

Access the full session

Poster session 4 - Stroke prevention

Speakers: Professor D. Vinereanu, Doctor A. Tyminska, Doctor M. Gupta, Professor H. Bonnemeier, Ms D. Loikas...
Thumbnail

About the event

Image

ESC CONGRESS 2017

26 August - 30 August 2017

Sessions Presentations

This platform is supported by

logo Novo Nordisk